These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22858929)

  • 1. The influence of matriptase-2 on prostate cancer in vitro: a possible role for β-catenin.
    Webb SL; Sanders AJ; Mason MD; Jiang WG
    Oncol Rep; 2012 Oct; 28(4):1491-7. PubMed ID: 22858929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
    Sanders AJ; Parr C; Martin TA; Lane J; Mason MD; Jiang WG
    J Cell Physiol; 2008 Sep; 216(3):780-9. PubMed ID: 18449907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
    Sanders AJ; Parr C; Davies G; Martin TA; Lane J; Mason MD; Jiang WG
    J Exp Ther Oncol; 2006; 6(1):39-48. PubMed ID: 17228523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis.
    Cheng TS; Chen WC; Lin YY; Tsai CH; Liao CI; Shyu HY; Ko CJ; Tzeng SF; Huang CY; Yang PC; Hsiao PW; Lee MS
    Cancer Prev Res (Phila); 2013 May; 6(5):495-505. PubMed ID: 23466486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
    Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
    Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer.
    Davies G; Ablin RJ; Mason MD; Jiang WG
    J Exp Ther Oncol; 2007; 6(3):257-64. PubMed ID: 17552366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
    Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
    Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
    Tsui KH; Chang PL; Feng TH; Chung LC; Sung HC; Juang HH
    Anticancer Res; 2008; 28(4A):1993-9. PubMed ID: 18649738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.
    Webb SL; Sanders AJ; Mason MD; Jiang WG
    Mol Cell Biochem; 2013 Mar; 375(1-2):207-17. PubMed ID: 23238872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
    Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolytic processing of the serine protease matriptase-2: identification of the cleavage sites required for its autocatalytic release from the cell surface.
    Stirnberg M; Maurer E; Horstmeyer A; Kolp S; Frank S; Bald T; Arenz K; Janzer A; Prager K; Wunderlich P; Walter J; Gütschow M
    Biochem J; 2010 Aug; 430(1):87-95. PubMed ID: 20518742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.
    Hsieh IS; Chang KC; Tsai YT; Ke JY; Lu PJ; Lee KH; Yeh SD; Hong TM; Chen YL
    Carcinogenesis; 2013 Mar; 34(3):530-8. PubMed ID: 23188675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
    Davies G; Watkins G; Mason MD; Jiang WG
    Prostate; 2004 Sep; 60(4):317-24. PubMed ID: 15264243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness.
    Baba T; Kawaguchi M; Fukushima T; Sato Y; Orikawa H; Yorita K; Tanaka H; Lin CY; Sakoda S; Kataoka H
    J Pathol; 2012 Oct; 228(2):181-92. PubMed ID: 22262311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.
    Wang H; McKnight NC; Zhang T; Lu ML; Balk SP; Yuan X
    Cancer Res; 2007 Jan; 67(2):528-36. PubMed ID: 17234760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
    Tsui KH; Chang PL; Feng TH; Chung LC; Hsu SY; Juang HH
    Anticancer Res; 2008; 28(4A):1977-83. PubMed ID: 18649735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From prediction to experimental validation: desmoglein 2 is a functionally relevant substrate of matriptase in epithelial cells and their reciprocal relationship is important for cell adhesion.
    Wadhawan V; Kolhe YA; Sangith N; Gautam AK; Venkatraman P
    Biochem J; 2012 Oct; 447(1):61-70. PubMed ID: 22783993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.
    Morton RA; Ewing CM; Nagafuchi A; Tsukita S; Isaacs WB
    Cancer Res; 1993 Aug; 53(15):3585-90. PubMed ID: 8339265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration.
    Liu JW; Shen JJ; Tanzillo-Swarts A; Bhatia B; Maldonado CM; Person MD; Lau SS; Tang DG
    Oncogene; 2003 Mar; 22(10):1475-85. PubMed ID: 12629510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.
    Oh JJ; Taschereau EO; Koegel AK; Ginther CL; Rotow JK; Isfahani KZ; Slamon DJ
    Lung Cancer; 2010 Dec; 70(3):253-62. PubMed ID: 20338664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.